These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

710 related items for PubMed ID: 19006173

  • 1. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
    Huang HM, Liu JC.
    J Cell Physiol; 2009 Mar; 218(3):568-74. PubMed ID: 19006173
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N, Koschmieder S, Tyagi S, Portero-Robles I, Chromic J, Myloch S, Nürnberger H, Rossmanith T, Hofmann WK, Hoelzer D, Ottmann OG.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [Abstract] [Full Text] [Related]

  • 3. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
    Jacquel A, Colosetti P, Grosso S, Belhacene N, Puissant A, Marchetti S, Breittmayer JP, Auberger P.
    Oncogene; 2007 Apr 12; 26(17):2445-58. PubMed ID: 17043649
    [Abstract] [Full Text] [Related]

  • 4. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
    Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, Varticovski L, Dent P, Grant S.
    Cancer Res; 2003 May 01; 63(9):2118-26. PubMed ID: 12727828
    [Abstract] [Full Text] [Related]

  • 5. Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line.
    Rabizadeh E, Merkin V, Belyaeva I, Shaklai M, Zimra Y.
    Leuk Res; 2007 Aug 01; 31(8):1115-23. PubMed ID: 17267032
    [Abstract] [Full Text] [Related]

  • 6. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.
    Clin Cancer Res; 2009 Mar 01; 15(5):1686-97. PubMed ID: 19240172
    [Abstract] [Full Text] [Related]

  • 7. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
    Cheong JW, Chong SY, Kim JY, Eom JI, Jeung HK, Maeng HY, Lee ST, Min YH.
    Clin Cancer Res; 2003 Oct 15; 9(13):5018-27. PubMed ID: 14581377
    [Abstract] [Full Text] [Related]

  • 8. Basic fibroblast growth factor inhibits p38-mediated cell differentiation and growth inhibition by activin A but not by histone deacetylase inhibitors in CML cells.
    Chen CH, Lin JY, Liu FH, Chang JL, Huang HM.
    Ann Hematol; 2008 Mar 15; 87(3):175-82. PubMed ID: 17929017
    [Abstract] [Full Text] [Related]

  • 9. In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors.
    Brieger A, Boehrer S, Schaaf S, Nowak D, Ruthardt M, Kim SZ, Atadja P, Hoelzer D, Mitrou PS, Weidmann E, Chow KU.
    Biochem Pharmacol; 2004 Jul 01; 68(1):85-93. PubMed ID: 15183120
    [Abstract] [Full Text] [Related]

  • 10. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
    Yu C, Krystal G, Dent P, Grant S.
    Clin Cancer Res; 2002 Sep 01; 8(9):2976-84. PubMed ID: 12231544
    [Abstract] [Full Text] [Related]

  • 11. STI571 and morpholine derivative of doxorubicin collaborate in inhibition of K562 cell proliferation by inducing differentiation and mitochondrial pathway of apoptosis.
    Jakubowska J, Wasowska-Lukawska M, Czyz M.
    Eur J Pharmacol; 2008 Oct 31; 596(1-3):41-9. PubMed ID: 18782571
    [Abstract] [Full Text] [Related]

  • 12. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
    Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ.
    Clin Cancer Res; 2004 Oct 01; 10(19):6661-8. PubMed ID: 15475456
    [Abstract] [Full Text] [Related]

  • 13. Different roles of p38 MAPK and ERK in STI571-induced multi-lineage differentiation of K562 cells.
    Kohmura K, Miyakawa Y, Kawai Y, Ikeda Y, Kizaki M.
    J Cell Physiol; 2004 Mar 01; 198(3):370-6. PubMed ID: 14755542
    [Abstract] [Full Text] [Related]

  • 14. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.
    Rahmani M, Reese E, Dai Y, Bauer C, Kramer LB, Huang M, Jove R, Dent P, Grant S.
    Mol Pharmacol; 2005 Apr 01; 67(4):1166-76. PubMed ID: 15625278
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
    Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R.
    Oncogene; 2002 Dec 12; 21(57):8804-16. PubMed ID: 12483533
    [Abstract] [Full Text] [Related]

  • 16. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
    Bright SA, Greene LM, Greene TF, Campiani G, Butini S, Brindisi M, Lawler M, Meegan MJ, Williams DC, Zisterer DM.
    Biochem Pharmacol; 2009 Feb 01; 77(3):310-21. PubMed ID: 19014913
    [Abstract] [Full Text] [Related]

  • 17. Combined effects of doxorubicin and STI571 on growth, differentiation and apoptosis of CML cell line K562.
    Jakubowska J, Stasiak M, Szulawska A, Bednarek A, Czyz M.
    Acta Biochim Pol; 2007 Feb 01; 54(4):839-46. PubMed ID: 17957275
    [Abstract] [Full Text] [Related]

  • 18. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS, Liu DS, Dai CW, Li RJ.
    Am J Hematol; 2006 Apr 01; 81(4):242-55. PubMed ID: 16550520
    [Abstract] [Full Text] [Related]

  • 19. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
    Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P, Bhalla K.
    Cancer Res; 2003 Aug 15; 63(16):5126-35. PubMed ID: 12941844
    [Abstract] [Full Text] [Related]

  • 20. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
    Majsterek I, Sliwinski T, Poplawski T, Pytel D, Kowalski M, Slupianek A, Skorski T, Blasiak J.
    Mutat Res; 2006 Jan 31; 603(1):74-82. PubMed ID: 16388976
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.